• Profile
Close

Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia

Gastroenterology May 24, 2018

Terrault N, et al. - In patients with thrombocytopenia and chronic liver disease (CLD) undergoing scheduled procedures, the researchers performed 2 randomized, placebo-controlled, phase 3 trials to assess the safety and efficacy of avatrombopag in increasing platelet counts in this patient population. From February 2014 through January 2017, ADAPT-1 was conducted at 75 study sites in 20 countries. From December 2013 through January 2017, ADAPT-2 was conducted at 74 sites in 16 countries. They discovered that avatrombopag was superior to placebo in lessening the need for platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD undergoing a scheduled procedure in 2 phase 3 randomized trials.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay